about
Mutant p53 interactome identifies nardilysin as a p53R273H-specific binding partner that promotes invasionThe hnRNP family: insights into their role in health and diseaseOncogenic Intra-p53 Family Member Interactions in Human CancersHallmarks of glycosylation in cancerMutant p53 Drives Cancer by Subverting Multiple Tumor Suppression PathwaysMutant p53: Multiple Mechanisms Define Biologic Activity in CancerKrüppel-like factor 17, a novel tumor suppressor: its low expression is involved in cancer metastasisTranscriptional control of cancer metastasisResistance and gain-of-resistance phenotypes in cancers harboring wild-type p53Tumor suppressor p53 and its mutants in cancer metabolismThe laminin response in inflammatory bowel disease: protection or malignancy?Caught in the cross fire: p53 in inflammation.Gain of function of mutant p53: R282W on the peak?Role of DNA repair machinery and p53 in the testicular germ cell cancer: a reviewThe Regulation of Tumor Suppressor p63 by the Ubiquitin-Proteasome SystemNovel role of PELP1 in regulating chemotherapy response in mutant p53-expressing triple negative breast cancer cellsPredicting transcriptional activity of multiple site p53 mutants based on hybrid propertiesInactivation and inducible oncogenic mutation of p53 in gene targeted pigsMinnelide/Triptolide Impairs Mitochondrial Function by Regulating SIRT3 in P53-Dependent Manner in Non-Small Cell Lung CancerClonal Evolutionary Analysis during HER2 Blockade in HER2-Positive Inflammatory Breast Cancer: A Phase II Open-Label Clinical Trial of Afatinib +/- VinorelbineDeterminants of the rate of protein sequence evolutionParsing Disease-relevant Protein Modifications from Epiphenomena: Perspective on the Structural Basis of SOD1-Mediated ALS.Base changes in tumour DNA have the power to reveal the causes and evolution of cancer.Mutant p53 promotes tumor progression and metastasis by the endoplasmic reticulum UDPase ENTPD5.Mutant p53 Protein and the Hippo Transducers YAP and TAZ: A Critical Oncogenic Node in Human Cancers.Significance of TP53 mutations as predictive markers of adjuvant cisplatin-based chemotherapy in completely resected non-small-cell lung cancer.BRMS1 suppresses lung cancer metastases through an E3 ligase function on histone acetyltransferase p300.A novel PTEN/mutant p53/c-Myc/Bcl-XL axis mediates context-dependent oncogenic effects of PTEN with implications for cancer prognosis and therapyMutant p53 enhances MET trafficking and signalling to drive cell scattering and invasion.Mutant p53-associated myosin-X upregulation promotes breast cancer invasion and metastasis.p53 in cell invasion, podosomes, and invadopodiaMonoclonal antibody against the ectodomain of E-cadherin (DECMA-1) suppresses breast carcinogenesis: involvement of the HER/PI3K/Akt/mTOR and IAP pathwaysmiR-600 inhibits cell proliferation, migration and invasion by targeting p53 in mutant p53-expressing human colorectal cancer cell lines.Wild-type and mutant p53 differentially regulate NADPH oxidase 4 in TGF-β-mediated migration of human lung and breast epithelial cellsCharacterization of a new mouse p53 variant: loss-of-function and gain-of-function.High-resolution network biology: connecting sequence with function.The dichotomy of p53 regulation by noncoding RNAs.TP53 mutations in human cancers: origins, consequences, and clinical useEffectiveness of imatinib mesylate over etoposide in the treatment of sensitive and resistant chronic myeloid leukaemia cells in vitroMouse models of p53 functions.
P2860
Q24337116-A0472538-ECD7-42B4-9A19-C5586B5DBE6BQ26746566-0762E88A-5C9C-4570-98DF-2AC37C1063BBQ26749382-AF978DF3-22B4-4FC6-8881-F2AA1381E7F3Q26752363-C51F090F-481F-4E5D-A8E8-5E1B951339D1Q26767396-71BA22ED-D878-42B4-8665-227F96DD9D7DQ26776020-E75D9749-D66C-4EB7-9A09-3E0DA650112EQ26776349-2F41C10B-6FF9-42D5-925B-1D7A33EE3E9BQ26992024-49076398-706C-4853-BE69-9720A2D1EA4CQ27006998-1A14C41A-9342-4F09-931A-708799D34FDAQ27010683-F75AFE69-9DD0-4891-A4A5-743F5D94A19AQ27333814-99DB8A5F-1828-439D-90FD-EBF3DC3DD2BEQ27692076-634E1997-F092-48AE-9587-FE114A15C314Q28068551-6D1E59AF-AB66-4D8E-A230-46D5A08EF912Q28069963-DA6EA98C-DD1A-41D0-A970-8491F7FEA380Q28078288-986BE5B7-E33F-4316-B434-13CF3EB97461Q28259152-F80C3F51-00E9-41B9-8C41-22087E519951Q28476462-893DACCA-5DC8-4F94-91E9-384E4E378046Q28484241-A15442E0-3332-4E39-BD0C-0FB358F66513Q28553412-390EDD4C-DFA7-47B9-8FAD-CCD32CA8763BQ28554790-3AA4698B-356F-483D-BA32-B2F532FF21FEQ28645761-F1FC5804-A7AD-4570-B936-D80D56477DCCQ30101060-5FA3BF32-0BBA-4C99-9CBF-09EDD76B54B0Q30249783-1C1B4CFF-911A-44DD-91D9-85A15397C493Q30313610-7934375B-8FFE-4F76-BF2B-869E1F484916Q30354662-6E0FACE5-94E0-405A-BF7F-C60494F5CC45Q30358684-73CBA930-E54F-4D83-BCD4-BCD446207ABEQ30414771-08FF90C0-A43A-4102-A10D-F32A7F035C12Q30417988-CDCDD6FB-6D4F-4C52-A213-D450937F4FAAQ30537354-793F7B47-687A-485D-869B-0C488D326157Q30572690-0E2E6781-2BEB-457C-8300-4418A5399858Q33358202-0B2537E0-771D-4D8B-A035-1FAF423FCADEQ33584432-3AC44FA4-8D4D-4863-8657-2717394A77C6Q33599315-F90B3DC6-9BD8-42CC-8EBE-28740A171A37Q33613596-CF047318-B330-4FFF-A5C2-82A0A72AACCBQ33617456-7C01CB88-1047-41F0-BE63-8872621AEE97Q33623110-7A66597A-0D5C-453F-BE87-9F7F3012D772Q33668469-E9368917-561E-4434-899D-83A4213D542FQ33685392-E3398092-D703-40C1-BFDF-8A3D04BE35AAQ33744180-7840A8E5-BE4B-476A-8F2D-A6DD8B6E23E0Q33752174-65A0061B-7968-43CD-8173-9E4F96BC5436
P2860
description
2010 nî lūn-bûn
@nan
2010 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Mutant p53 gain-of-function in cancer.
@ast
Mutant p53 gain-of-function in cancer.
@en
type
label
Mutant p53 gain-of-function in cancer.
@ast
Mutant p53 gain-of-function in cancer.
@en
prefLabel
Mutant p53 gain-of-function in cancer.
@ast
Mutant p53 gain-of-function in cancer.
@en
P2860
P1476
Mutant p53 gain-of-function in cancer.
@en
P2093
Moshe Oren
Varda Rotter
P2860
P304
P356
10.1101/CSHPERSPECT.A001107
P577
2010-02-01T00:00:00Z